Merck says will not seek approval of cholesterol treatment
(Reuters Health)

(Reuters) - Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings.